Search results
Showing 151 to 200 of 314 results for breast cancer
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued Reference number: GID-TA10570
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Discontinued Reference number: GID-TA10591
Digital AI tools in histopathology (breast and prostate cancer)
Awaiting development Reference number: GID-HTE10087 Expected publication date: TBC
Awaiting development Reference number: GID-TA10896 Expected publication date: TBC
In development Reference number: GID-TA11342 Expected publication date: TBC
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued Reference number: GID-TA10309
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued Reference number: GID-TA11261
Discontinued Reference number: GID-TA10803
Irreversible electroporation for treating primary lung cancer and metastases in the lung (HTG302)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for HTG302Show all sections
Sections for HTG302
Awaiting development Reference number: GID-TA11487 Expected publication date: TBC
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued Reference number: GID-TA10539
In development Reference number: GID-TA11658 Expected publication date: TBC
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
Discontinued Reference number: GID-TA10531
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]
Discontinued Reference number: GID-TA11178
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Discontinued Reference number: GID-TAG410
Image-guided percutaneous laser ablation for primary and secondary liver tumours (HTG722)
Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.
View recommendations for HTG722Show all sections
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Discontinued Reference number: GID-TAG391
Discontinued Reference number: GID-TAG432
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development Reference number: GID-TA11022 Expected publication date: TBC
Awaiting development Reference number: GID-TA11720 Expected publication date: TBC
Discontinued Reference number: GID-TA10028
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued Reference number: GID-TA10327
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
Discontinued Reference number: GID-TAG390
Discontinued Reference number: GID-TA10264
Awaiting development Reference number: GID-TA11110 Expected publication date: TBC
Discontinued Reference number: GID-TAG436
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.
In development Reference number: GID-TA11687 Expected publication date: TBC
In development Reference number: GID-TA10261 Expected publication date: TBC
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued Reference number: GID-TAG411
In development Reference number: GID-TA11400 Expected publication date: TBC
Recommendation ID NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in...
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
Discontinued Reference number: GID-TAG417
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026
combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012 Other
guidance details Comes from guidance Early and locally advanced breast cancer: diagnosis and management Number NG101 Date issued
combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011 Other